A 26 Week Treatment, Randomized, Multi Center, Double Blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 microg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 microg b.i.d.) as an Active Control.

Trial Profile

A 26 Week Treatment, Randomized, Multi Center, Double Blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 microg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 microg b.i.d.) as an Active Control.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 09 Jun 2012 Additional company (GlaxoSmithKline) added in association as reported by European Clinical Trials Database.
    • 22 Jul 2011 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top